Merz Therapeutics and Teijin Secure Japan Approval for XEOMIN®
TOKYO, Japan and FRANKFURT, Germany, June 19, 2026 Teijin Pharma Limited and Merz Therapeutics GmbH have announced that Japan’s...
Merz Therapeutics
Advertisement
Merz Therapeutics Unveils New Insights Into Parkinson’s OFF Episodes at WPC 2026
FRANKFURT, Germany & RALEIGH, N.C. — May 28, 2026 Merz Therapeutics presented new research at the World Parkinson Congress...
Myosin Therapeutics Advances MT-125 as Key Oncology Milestone Nears
JUPITER, Florida | January 29, 2026 — Myosin Therapeutics, a clinical-stage biotechnology company focused on first-in-class oncology therapies, has...
Merz Therapeutics Names Dan Staner President of Europe
Frankfurt, Germany – January 30, 2026 — Merz Therapeutics has announced the appointment of Dan Staner as President, Region...
Advertisement
